Trials / Withdrawn
WithdrawnNCT04699968
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
Phase II Clinical Trial of SHR-1701 With or Without Famitinib in the Treatment of Advanced or Metastatic NSCLC
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701，Famitinib | SHR -1701, Intravenous ；Famitinib, oral |
| DRUG | SHR-1701 | SHR -1701, Intravenous |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
- First posted
- 2021-01-07
- Last updated
- 2023-06-07
Source: ClinicalTrials.gov record NCT04699968. Inclusion in this directory is not an endorsement.